Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 70/100

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Thursday, August 22, 2024 1 min read
Key Takeaway: Eton Pharmaceuticals, a company focused on rare disease treatments, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. CEO Sean Brynjelsen will present on September 9, 2024, with the session available on demand. This conference serves as a platform for Eton to connect with investors and share insights into its innovative product pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is actively participating in an influential investment conference.
  • The company showcases its innovative approach to developing treatments for rare diseases.
  • Involvement in the conference may enhance visibility and attract potential investors.

Full Press Release Details

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
The Company’s presentation by Sean Brynjelsen, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7am ET.
Investors can access the presentation here.
To schedule an in-person 1x1 meeting with the Company, please contact Corporate Access at H.C. Wainwright.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.

Frequently Asked Questions

When will Eton Pharmaceuticals present at the conference?

Eton Pharmaceuticals will present on September 9, 2024, at 7am ET.

How can investors access Eton's conference presentation?

Investors can access the presentation through a link provided by Eton.

What rare disease products does Eton currently offer?

Eton offers ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone.

What new product candidates are in Eton's development pipeline?

Eton has ET-400, ET-600, and ZENEO® hydrocortisone autoinjector in late-stage development.

Who is the CEO of Eton Pharmaceuticals?

Sean Brynjelsen is the Chief Executive Officer of Eton Pharmaceuticals.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals H.C. Wainwright investment conference rare diseases ET-400
Last updated: Aug 22, 2024